Nanoparticles Could Slow Rheumatoid Arthritis Progression and Reduce Flare Severity
LOS ANGELES, CALIFORNIA, AUG 6 – Nanoparticles called Agg-CLNP reduced rheumatoid arthritis flare severity by 50% in mice and may enhance combination therapies by targeting immune cells, researchers reported.
4 Articles
4 Articles
Nanoparticles could slow rheumatoid arthritis progression and reduce flare severity
As a chronic condition, rheumatoid arthritis (RA) can't be cured, so treatment focuses on managing the disease and controlling its progression. Although current treatments help control RA symptoms in most people, they cannot prevent the onset of RA or painful flare-ups.
Arthritis Treatment Reduces Painful Flare-Ups, Slows Disease
Voice is AI-generated. Inconsistencies may occur. A new therapeutic approach for rheumatoid arthritis (RA) could help prolong the time between flare-ups and even prevent the onset of the disease in at-risk patients. This is the promise of a new study by researchers who have developed nanoparticles…
Nanoparticles Slow Disease Progression and Reduce Flare Severity in RA Mouse Model
Rheumatoid arthritis (RA) is a chronic, incurable disorder, so treatment focuses on managing the disease and controlling its progression. Although current treatments help control RA symptoms in most people, they cannot prevent the onset of RA or painful flare-ups. Researchers headed by teams at Kao Autoimmunity Institute and Division of Rheumatology, Cedars-Sinai Medical Center, and at the Department of Chemical and Nano Engineering, University …
New targeted rheumatoid arthritis drug delays disease, reduces flare-ups
A new nanoparticle drug has shown preclinical promise in both preventing rheumatoid arthritis and reducing painful flare-ups, offering hope for a targeted, steroid-sparing treatment that calms the immune system without widespread suppression.Continue ReadingCategory: Illnesses and conditions, Body & MindTags: Rheumatoid arthritis, Nanoparticles, Immunotherapy, Autoimmune
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium